Table 2.
Human cell lines originated from ovarian cancer or human ovarian surface epithelium
|
ID number |
Cell line |
Origin |
Source |
|---|---|---|---|
| Homo sapiens – human | |||
| 1 |
222 |
|
|
| 2 |
2008 |
Ovary |
|
| 3 |
2008/C13.R |
Ovarian adenocarcinoma |
NCBI |
| 4 |
41Ma/OAW28 |
Ovarian cancer ascites |
ECACC |
| 5 |
41 M cisR |
Ovarian cancer ascites |
|
| 6 |
59 M |
Ovarian cancer ascites |
ECACC |
| 7 |
A2780 |
Ovarian adenocarcinoma |
ECACC |
| 8 |
A2780ADR |
Ovarian adenocarcinoma; A2780 |
ECACC |
| 9 |
A2780cis |
Ovarian adenocarcinoma; A2780 |
ECACC |
| 10 |
A2780 CP |
Ovarian adenocarcinoma |
NCBI |
| 11 |
A2780 S |
Ovarian adenocarcinoma |
NCBI |
| 12 |
Caov-3 |
Ovarian adenocarcinoma |
ATCC |
| 13 |
Caov-4 |
Metastatic fallopian tube mass from ovarian tumour |
ATCC/NCBI |
| 14 |
CH1 |
Ovarian adenocarcinoma |
|
| 15 |
CH1cisR |
Ovarian adenocarcinoma |
|
| 16 |
COLO-704 |
Metastatic colonic ascites from ovarian tumour |
DSMZ |
| 17 |
COV318 |
Ovarian cancer ascites |
ECACC |
| 18 |
COV362 |
Ovarian cancer pleural effusion |
ECACC |
| 19 |
COV362.4 |
Ovarian cancer pleural effusion; COV362 |
ECACC |
| 20 |
COV413A |
Metastatic sigmoid mass from ovarian tumour |
ECACC |
| 21 |
COV413B |
Metastatic bladder dome mass from ovarian tumour |
ECACC |
| 22 |
COV434 |
Ovarian granulosa tumour from a solid primary tumour |
ECACC |
| 23 |
COV504 |
Ovarian pleural effusion |
ECACC |
| 24 |
COV644 |
Ovarian cancer (primary tumor) |
ECACC |
| 25 |
EFO-21 |
Ovarian cancer ascites |
DSMZ |
| 26 |
EFO27 |
Metastatic omental mass from ovarian tumour |
DSMZ |
| 27 |
ES-2 |
Ovarian adenocarcinoma |
ATCC |
| 28 |
FU-OV-1 |
Malignant ovarian mass |
DSMZ |
| 29 |
HAC-2 |
Ovarian cancer cell derived from mesonephros |
JCRB |
| 30 |
Hey-A8 |
Ovary |
CCLE |
| 31 |
HOSE 6-3 |
Ovarian surface epithelium |
|
| 32 |
HOSE 17-1 |
Ovarian surface epithelium |
|
| 33 |
HOSE 105 |
Ovarian surface epithelium |
|
| 34 |
HOSE 111 |
Ovarian surface epithelium |
|
| 35 |
HOSE 129 |
Ovarian surface epithelium |
|
| 36 |
HOSE 130 |
Ovarian surface epithelium |
|
| 37 |
Hs 38.T |
Ovarian teratoma |
ATCC |
| 38 |
Hs 571.T |
Ovarian adenocarcinoma |
ATCC |
| 39 |
Hs904.T |
|
|
| 40 |
IGROV1 |
Ovarian adenocarcinoma |
|
| 41 |
JHOC-5 |
Ovarian adenocarcinoma |
CCLE |
| 42 |
JHOM-1 |
Ovarian adenocarcinoma |
CCLE |
| 43 |
JHOM-2B |
Ovarian adenocarcinoma |
CCLE |
| 44 |
JHOS-2 |
Ovarian adenocarcinoma |
CCLE |
| 45 |
JHOS-4 |
Ovarian adenocarcinoma |
CCLE |
| 46 |
KURAMOCHI |
Ovarian cancer ascites |
JCRB |
| 47 |
MCAS |
Ovarian adenocarcinoma |
JCRB |
| 48 |
NCC-OvC-K119 |
Ovarian adenocarcinoma |
JCRB |
| 49 |
OAW28/41 M |
Ovarian cancer ascites |
ECACC |
| 50 |
OAW42 |
Ovarian cancer ascites |
ECACC |
| 51 |
OC 314 |
Ovarian cancer ascites |
CCLE |
| 52 |
OC 315 |
Ovarian adenocarcinoma |
CCLE |
| 53 |
OC 316 |
Ovarian cancer ascites |
CCLE |
| 54 |
ONCO-DG-1a |
Ovarian adenocarcinoma |
DSMZ |
| 55 |
OV-7 |
Ovarian adenocarcinoma derived from solid tumour |
ECACC |
| 56 |
OV17R |
Ovarian cancer ascites |
ECACC |
| 57 |
OV56 |
Ovarian cancer ascites |
ECACC |
| 58 |
OV-58 |
Ovarian cancer ascites |
ECACC |
| 59 |
OV-90 |
Ovarian cancer ascites |
ATCC |
| 60 |
OV-1063a |
|
|
| 61 |
OVC1-PI 32 |
Ovary |
NCBI |
| 62 |
OVCAR-3 |
Ovarian cancer ascites |
ATCC/NCBI |
| 63 |
OVCAR-4 |
Ovarian adenocarcinoma |
CCLE |
| 64 |
OVCAR-8 |
Ovarian adenocarcinoma |
CCLE |
| 65 |
OVISE |
Metastatic ovarian adenocarcinoma |
JCRB/CCLE |
| 66 |
OVK18 |
Ovarian adenocarcinoma |
CCLE |
| 67 |
OVKATE |
Ovarian adenocarcinoma |
JCRB |
| 68 |
OVMANA |
Ovarian adenocarcinoma |
JCRB |
| 69 |
OVMIUa |
Ovarian adenocarcinoma |
JCRB |
| 70 |
OVMIU-IIa |
Ovarian adenocarcinoma |
JCRB |
| 71 |
OVSAHO |
Ovarian adenocarcinoma |
JCRB |
| 72 |
OVSAYOa |
Ovarian adenocarcinoma |
JCRB |
| 73 |
OVTOKO |
Ovarian adenocarcinoma |
JCRB |
| 74 |
PA-1 |
Ovarian cancer ascites |
ATCC/JCRB/ECACC |
| 75 |
PA-1/6TG-r |
Ovarian cancer ascites |
JCRB |
| 76 |
PEA1 |
Ovarian cancer pleural effusion |
ECACC |
| 77 |
PEA2 |
Ovarian cancer ascites |
ECACC |
| 78 |
PEO1 |
Ovarian cancer ascites |
ECACC |
| 79 |
PEO4 |
Ovarian cancer pleural effusion |
ECACC |
| 80 |
PEO6 |
Ovarian cancer ascites |
ECACC |
| 81 |
PEO14b |
Ovarian cancer ascites |
ECACC |
| 82 |
PEO16 |
Ovarian cancer ascites |
ECACC |
| 83 |
PEO23b |
Ovarian cancer ascites |
ECACC |
| 84 |
RKN |
Ovarian adenocarcinoma |
JCRB |
| 85 |
RMG-Ia |
Ovarian adenocarcinoma |
JCRB |
| 86 |
RMG-II |
Ovarian adenocarcinoma |
JCRB |
| 87 |
RMUG-La |
Ovarian adenocarcinoma |
JCRB |
| 88 |
RMUG-S |
Ovarian adenocarcinoma |
JCRB |
| 89 |
RTSGc |
Ovarian adenocarcinoma |
JCRB |
| 90 |
SCC60 |
|
|
| 91 |
SK-OV-3 |
Ovarian cancer ascites |
ATCC/NCBI/ECACC |
| 92 |
SNU-8 |
Ovarian adenocarcinoma |
CCLE |
| 93 |
SNU-119 |
Ovarian adenocarcinoma |
CCLE |
| 94 |
SNU-840 |
Ovarian adenocarcinoma |
CCLE |
| 95 |
SW 626 |
Ovarian metastatic mass from colon tumour |
ATCC/ECACC |
| 96 |
TE 84.T |
Ovarian adenocarcinoma |
ATCC |
| 97 |
TO14b |
Metastatic omental mass from ovarian tumour |
ECACC |
| 98 |
TOV-21G |
Malignant ovarian mass |
ATCC |
| 99 |
TOV-81D |
Malignant ovarian mass |
|
| 100 |
TOV-112D |
Malignant ovarian mass |
ATCC |
| 101 |
TYK-nu |
Ovarian adenocarcinoma |
JCRB |
| 102 |
TYK-nu.CP-r |
Ovarian adenocarcinoma |
JCRB |
| 103 |
UC1-101 |
Ovarian adenocarcinoma |
|
| 104 | UC1-107 | ||
aPossible cross contamination or misidentification (JCRB, DSMZ: Database of Cross-Contaminated or misidentified cell lines, Capes-Davis, A. and Freshney, R.I. Version 6.7, Table 1 27.6.2011). Cross contaminated with OVCAR-3 (ONCO-DG-1); bAll these cell lines were derived from the same patient.